Truncated form of beta-catenin and reduced expression of wild-type catenins feature HepG2 human liver cancer cells.
about
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cellsTargeted therapy for hepatocellular carcinoma: novel agents on the horizonHepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcriptionIdentification and characterization of a novel small-molecule inhibitor of β-catenin signalingRole of miR-148a in hepatitis B associated hepatocellular carcinoma.Comparison of the regulation of β-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells.Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice.siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survivalHBx triggers either cellular senescence or cell proliferation depending on cellular phenotype.β-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid.Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin.Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction.C9orf140, a novel Axin1-interacting protein, mediates the negative feedback loop of Wnt/β-catenin signaling.
P2860
Q24669950-E29827E9-0CD8-4DE3-9BA5-5EB1DE1F20CEQ27002288-DC4E7695-00BE-405E-A81A-6557B8986CC3Q27469443-62AC04A1-F7AC-4AB6-9751-BE01411D9D61Q30384345-490B053F-3F62-4F8D-9E7F-3357038272B4Q34230585-83750F83-CA5E-4EFB-BBDA-CB32D4668338Q34442738-19FD2BFE-436C-4283-9E37-842F0C47471CQ34988085-CFF53538-940A-4F54-B91B-FC55BE817285Q35077956-AD4EC820-5AA0-406D-9F01-151890A2E170Q36143616-82E6C335-4538-43D7-ABC9-3C2FC4E22A8BQ38840132-A17ADA81-FB09-454B-9EC2-567A12718E04Q39131067-52FC43EE-6AA8-4780-AF2D-E1E597E7A93FQ41494111-0C9A2DC1-0AD7-4CBA-8B22-3ABAA81BB3B7Q42830004-5A33055A-13EF-4665-B1E2-3662900F2077Q51209998-F17C556A-E754-4F8A-BE36-9D390654C3BBQ52659500-D3127810-56C6-4750-B509-0083CA4544F0
P2860
Truncated form of beta-catenin and reduced expression of wild-type catenins feature HepG2 human liver cancer cells.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@ast
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@en
type
label
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@ast
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@en
prefLabel
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@ast
Truncated form of beta-catenin ...... epG2 human liver cancer cells.
@en
P2093
P2860
P1476
Truncated form of beta-catenin ...... HepG2 human liver cancer cells
@en
P2093
G Montalto
L Castagnetta
L Giannitrapani
M Cervello
M D Miceli
M Notarbartolo
R Farruggio
P2860
P304
P356
10.1111/J.1749-6632.1999.TB09419.X
P407
P577
1999-01-01T00:00:00Z